Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-11 4:15 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | Samsara BioCapital, L.P. | 824,155 6.500% | 824,155 (New Position) | Filing History |
| 2024-10-11 4:00 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | Deep Track Capital LP | 684,156 5.410% | 684,156 (New Position) | Filing History |
| 2024-10-10 6:57 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | Perceptive Advisors LLC | 1,004,439 7.900% | 1,004,439 (New Position) | Filing History |
| 2024-10-10 4:30 pm Purchase | 2024-10-08 | 13D | OnKure Therapeutics, Inc. OKUR | Carlyle Group Inc. CG | 273,045 2.200% | 273,045 (New Position) | Filing History |
| 2024-10-09 4:01 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | ACORN BIOVENTURES, L.P. | 1,439,674 11.400% | 1,439,674 (New Position) | Filing History |
| 2024-10-09 11:40 am Purchase | 2024-10-09 | 13G | OnKure Therapeutics, Inc. OKUR | BML Investment Partners, L.P. | 447,815 3.500% | 447,815 (New Position) | Filing History |
| 2024-10-08 7:34 pm Sale | 2024-10-04 | 13D | Reneo Pharmaceuticals, Inc. RPHM | New Enterprise Associates 15 L.P. | 0 0.000% | -478,549 (Position Closed) | Filing History |
| 2024-09-26 4:00 pm Sale | 2023-12-26 | 13G | Reneo Pharmaceuticals, Inc. RPHM | TANG CAPITAL PARTNERS LP | 294,626 8.800% | -38,374 (-11.52%) | Filing History |
| 2024-05-21 10:12 am Purchase | 2024-05-21 | 13G | Reneo Pharmaceuticals, Inc. RPHM | BML Investment Partners, L.P. | 369,296 11.000% | 199,873 (+117.97%) | Filing History |
| 2024-05-08 4:33 pm Unchanged | 2024-05-07 | 13D | Reneo Pharmaceuticals, Inc. RPHM | New Enterprise Associates 15 L.P. | 478,549 14.300% | 0 (Unchanged) | Filing History |
| 2024-02-05 4:01 pm Purchase | 2023-12-31 | 13G | Reneo Pharmaceuticals, Inc. RPHM | Octagon Capital Advisors LP | 225,000 6.750% | 225,000 (New Position) | Filing History |
| 2024-01-16 5:54 pm Purchase | 2024-01-10 | 13G | Reneo Pharmaceuticals, Inc. RPHM | BML Investment Partners, L.P. | 169,423 5.100% | 169,423 (New Position) | Filing History |
| 2023-12-26 5:00 pm Purchase | 2023-11-14 | 13D | Reneo Pharmaceuticals, Inc. RPHM | TANG CAPITAL PARTNERS LP | 333,000 9.996% | 333,000 (New Position) | Filing History |
| 2023-12-15 4:55 pm Sale | 2023-12-14 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Novo Holdings A/S | 0 0.000% | -343,038 (Position Closed) | Filing History |
| 2023-05-30 4:52 pm Purchase | 2023-05-08 | 13D | Reneo Pharmaceuticals, Inc. RPHM | RiverVest Venture Fund III, L.P. | 253,422 7.530% | 12,500 (+5.19%) | Filing History |
| 2023-05-15 5:16 pm Unchanged | 2023-05-09 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Novo Holdings A/S | 343,038 10.200% | 0 (Unchanged) | Filing History |
| 2023-05-09 4:31 pm Purchase | 2023-05-02 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Carlyle Group Inc. CG | 273,046 8.200% | 64,250 (+30.77%) | Filing History |
| 2022-09-30 4:45 pm Unchanged | 2022-09-27 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Novo Holdings A/S | 343,038 14.000% | 0 (Unchanged) | Filing History |
| 2022-08-11 4:52 pm Purchase | 2022-08-01 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Carlyle Group Inc. CG | 208,796 8.500% | 208,796 (New Position) | Filing History |
| 2022-01-27 3:31 pm Unchanged | 2022-01-20 | 13D | Reneo Pharmaceuticals, Inc. RPHM | Novo Holdings A/S | 343,038 14.000% | 0 (Unchanged) | Filing History |